In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Brickell Biotech, Inc.

https://brickellbio.com/

Latest From Brickell Biotech, Inc.

Finance Watch: Restructurings, Layoffs Reflect Ongoing Uncertainty In Biotech

Sio Gene, Genocea, Solid Biosciences, Saniona and Black Diamond join First Wave, Zosano, Vallon, Finch, Magenta, ProQR and Imara on the growing list of biopharma firms reducing headcount to make their cash last until valuations return to a level that may support new fundraising. 

Financing Business Strategies

Tech Transfer Roundup: Lysogene Elects Option On Gene Therapy Discovered At Weizmann Institute

French biotech brings candidate for Gaucher and Parkinson’s disease in-house under 2020 pact with Weizmann. Cellevolve, Seattle Children’s partner on cell therapies for CNS cancers.

Tech Transfer Round-Up Deals

Trade Group Calls For mRNA Vaccines As Guangzhou Starts Lock Downs

Following Shanghai, China’s third-largest city Guangzhou is now on high alert as Omicron cases spread, while pharma and biotech face severe production and supply chain disruptions.

China Vaccines

TCMs Not Paxlovid Gain Traction As Beijing On High Alert

As Shanghai enters a second week of a city-wide lockdown with no signs of policy easing, officials are promoting the use of traditional Chinese medicines rather than Pfizer's recently approved Paxlovid.

China Coronavirus COVID-19
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Vical, Inc.
    • Vical Incorporated (VICL)
UsernamePublicRestriction

Register